CBI Laboratories, Inc.

Form 483 issued May 14, 2019 · Fort Worth, Texas

Inspection
May 9 – May 14, 2019
Observations
1
Pages
5

In short: On May 14, 2019, FDA issued a Form 483 with 1 observation to CBI Laboratories, Inc. in Fort Worth, Texas after an inspection that ran May 9 – May 14, 2019. The investigators were Michelle A. Krayer and Patty P. Kaewussdangkul. Most observations concern quality system; the most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit).

At a glance

1 of 1 observations on this 483 concern quality system.

Quality system1

Most cited: 21 CFR 211.22 (1×) · 211.192 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    The responsibilities and procedures applicable to the quality control unit…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at CBI Laboratories, Inc.?

FDA listed 1 observation on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit). The opening words of each observation are shown on this page.

Who inspected CBI Laboratories, Inc.?

Michelle A. Krayer and Patty P. Kaewussdangkul are named on this Form 483, for the inspection of May 9 – May 14, 2019. Each investigator has a profile showing what they cite most.

When was CBI Laboratories, Inc. inspected by FDA?

The inspection ran May 9 – May 14, 2019, and the Form 483 is dated May 14, 2019.

How do I get the full Form 483 for CBI Laboratories, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free